Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

NCT02332655 | Completed Phase 1 Results

• 1 other identifier: IRB00029264
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.

Conditions

Sturge-Weber Syndrome

Keywords

Sturge-Weber syndrome; SWS; Drug resistant epilepsy

Outcome Measures

Primary Outcomes (1)

• Number of Seizures Per Month

  A baseline seizure frequency was recorded for each subject in a diary for eight weeks prior to investigational drug initiation and parents/caregivers documented seizures on a daily basis throughout the trial using a seizure log. For assessing the efficacy of CBD, the investigator counted the change in frequency of seizures per month. The number of seizures within 56 days of the baseline and the number of seizures within 56 days of week 14 were calculated. Higher seizure frequency indicates worse outcome. This outcome is measured as the change in number of seizures per month between the baseline and week 14 time points.

  Measured within 56 days before baseline and 56 days before week 14

Secondary Outcomes (1)

• Percentage Change in Seizure Frequency at Most Recent Visit on CBD Compared With Baseline

  Measured at Baseline and most recent visit within 1 year

Study Arms (1)

Cannabidiol

EXPERIMENTAL

All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.

Drug: Cannabidiol

Interventions

Cannabidiol DRUG

Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given. The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed.

Also known as: Epidiolex, CBD

Cannabidiol

Eligibility Criteria

• Age: 1 Month - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Documentation of a diagnosis of drug resistant epilepsy as evidenced by failure to control seizures despite appropriate trial of two or more AEDs at therapeutic doses. Drug resistant epilepsy for this study is defined as: At least 1 reported quantifiable (no cluster or innumerable) defined seizure with motor signs per month for at least 3 months prior to initial visit and during the period between Visit 1 (Screening Visit) and Visit 2 (Baseline Visit), as per data captured in daily seizure diaries. These can be focal seizures, focal seizures with impaired consciousness, myoclonic seizures, generalized, and secondarily generalized seizures.
• Between 1-5 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment. Vagus nerve stimulator (VNS), ketogenic diet and modified Atkins diet do not count toward this limit.
• VNS must be on stable settings for a minimum of 3 months prior to enrollment.
• If on ketogenic or Atkins diet, must be on stable ratio for a minimum of 3 months prior to enrollment.
• Written informed consent obtained from the patient or the patient's legal representative must be obtained prior to beginning treatment.

You may not qualify if:

• Patients with seizures secondary to metabolic, toxic, infectious or psychogenic disorder or drug abuse or current seizures related to an acute medical illness.
• Presence of only non-motor partial seizures (without limb or facial movements, eye deviation or head turning)
• Patients who require rescue medication during the Baseline phase for more than 6 days.
• Patients with any severe and/or uncontrolled medical conditions at randomization such as:
• liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis \[i.e. quantifiable hepatitis B virus (HBV)-DNA and/or positive HbsAg, quantifiable hepatitis C virus (HCV)-RNA\]
• Uncontrolled diabetes as defined by fasting serum glucose \> 1.5
• Active (acute or chronic) or uncontrolled severe infections.
• Patients with an active, bleeding diathesis.
• Patients who have had a major surgery or significant traumatic injury within 4 weeks of study entry. Patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study.
• Patients who change the dose of the AEDs during 4 weeks before screening or during the baseline period.
• Prior treatment with any investigational drug within the preceding 4 weeks prior to study entry.
• Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study. Those in foster care, unable to keep follow-up appointments, maintain close contact with Principal Investigator, or complete all necessary studies to maintain safety.
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

Sponsors & Collaborators

• Anne Comi, MD: lead
• Jazz Pharmaceuticals: collaborator
• Faneca 66 Foundation: collaborator

Study Sites (1)

Kennedy Krieger Institute

Baltimore, Maryland, 21205, United States

Location

Related Links

• Hunter Nelson Sturge-Weber Center Website

MeSH Terms

Conditions

Sturge-Weber Syndrome; Drug Resistant Epilepsy

Interventions

Cannabidiol

Condition Hierarchy (Ancestors)

Hemangioma; Neoplasms, Vascular Tissue; Neoplasms by Histologic Type; Neoplasms; Neurocutaneous Syndromes; Nervous System Diseases; Angiomatosis; Vascular Diseases; Cardiovascular Diseases; Epilepsy; Brain Diseases; Central Nervous System Diseases

Intervention Hierarchy (Ancestors)

Cannabinoids; Terpenes; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: Dr. Anne Comi
• Organization: Kennedy Krieger Institute

comi@kennedykrieger.org

4439239172

Study Officials

• Anne M Comi, MD

  Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator, Director Sturge-Weber Center, Kennedy Krieger Institute, Professor Johns Hopkins University School of Medicine

Study Record Dates

• First Submitted: January 5, 2015
• First Posted: January 7, 2015
• Study Start: December 1, 2014
• Primary Completion: April 1, 2019
• Study Completion: April 1, 2021
• Last Updated: March 2, 2022
• Results First Posted: March 2, 2022

Record last verified: 2022-02

Locations

US (1)